179 related articles for article (PubMed ID: 11014565)
1. Evaluation of telomerase activity in cutaneous melanocytic proliferations.
Miracco C; Pacenti L; Santopietro R; Laurini L; Biagioli M; Luzi P
Hum Pathol; 2000 Sep; 31(9):1018-21. PubMed ID: 11014565
[TBL] [Abstract][Full Text] [Related]
2. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
3. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
4. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
[TBL] [Abstract][Full Text] [Related]
6. Telomerase activity in prognostic histopathologic features of melanoma.
Carvalho L; Lipay M; Belfort F; Santos I; Andrade J; Haddad A; Brunstein F; Ferreira L
J Plast Reconstr Aesthet Surg; 2006; 59(9):961-8. PubMed ID: 16920589
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
[TBL] [Abstract][Full Text] [Related]
8. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study.
Dyduch G; Okoń K; Pescarini E
Pol J Pathol; 2011 Sep; 62(3):139-44. PubMed ID: 22102069
[TBL] [Abstract][Full Text] [Related]
9. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma.
Wu K; Lund M; Bang K; Thestrup-Pedersen K
Cancer; 1999 Sep; 86(6):1056-63. PubMed ID: 10491534
[TBL] [Abstract][Full Text] [Related]
10. Malignant melanoma, dysplastic melanocytic nevi, and Spitz tumors. Histologic classification and characteristics.
Barnhill RL
Clin Plast Surg; 2000 Jul; 27(3):331-60, viii. PubMed ID: 10941557
[TBL] [Abstract][Full Text] [Related]
11. Telomerase activity in melanocytic lesions: A potential marker of tumor biology.
Rudolph P; Schubert C; Tamm S; Heidorn K; Hauschild A; Michalska I; Majewski S; Krupp G; Jablonska S; Parwaresch R
Am J Pathol; 2000 Apr; 156(4):1425-32. PubMed ID: 10751366
[TBL] [Abstract][Full Text] [Related]
12. Absence of telomerase activity and telemorase catalytic subunit mRNA in melanocyte cultures.
Dhaene K; Vancoillie G; Lambert J; Naeyaert JM; Van Marck E
Br J Cancer; 2000 Mar; 82(5):1051-7. PubMed ID: 10737388
[TBL] [Abstract][Full Text] [Related]
13. Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Clinicopathologic experience in a 100-bed hospital.
Duray PH; Ernstoff MS
Arch Dermatol; 1987 Jan; 123(1):80-4. PubMed ID: 3800426
[TBL] [Abstract][Full Text] [Related]
14. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
[TBL] [Abstract][Full Text] [Related]
15. Adhesion molecule profile and malignancy of melanocytic lesions.
Moretti S; Martini L; Berti E; Pinzi C; Giannotti B
Melanoma Res; 1993 Aug; 3(4):235-9. PubMed ID: 8219755
[TBL] [Abstract][Full Text] [Related]
16. Dysplastic melanocytic nevi and prognostically indeterminate nevomelanomatoid proliferations.
Kim JC; Murphy GF
Clin Lab Med; 2000 Dec; 20(4):691-712. PubMed ID: 11221510
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Singh RS; Diwan AH; Zhang PS; Prieto VG
J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
[TBL] [Abstract][Full Text] [Related]
18. The relationship between telomerase activity and proliferation in cutaneous melanoma.
Zamolo G; Coklo M; Bosnar A; Batinac T
Med Hypotheses; 2007; 68(1):125-7. PubMed ID: 16891062
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
20. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
